Device Trial Radar · NCT04177212
Investigation of the Effectiveness and Safety of MRZF111 in the Treatment of Décolleté Wrinkles
Last checked: Nov 20, 2026Latest source record: Dec 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
117
Actual
Start
Dec 4, 2019
Primary completion
Nov 17, 2020
Study completion Feb 23, 2021
Sponsor
- Lead sponsor
- Merz Aesthetics GmbHNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Merz Pharmaceuticals GmbH
- First posted
- Nov 26, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the effectiveness and safety of MRZF111 treatment for improvement of décolleté wrinkles as assessed on the Merz Aesthetics Scales (MAS) Décolleté Wrinkles-At Rest.
Conditions
- Décolleté Wrinkles
Interventions
MRZF111Device
MRZF111 kit consisting of one syringe of RADIESSE® Volume injectable implant, injection needles and additional components. Physiological saline solution (0.9% NaCl) is used to dilute Radiesse Volume by 1:2. Radiesse consists of calcium hydroxylapatite particles suspended in an aqueous-based gel carrier.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Responder Rate for Décolleté Wrinkles According to the Merz Aesthetics Scale (MAS)-At Rest Scale as Assessed by the Blinded Live RaterTime frame: 16 weeks after the last treatment on Week 16 (at Week 32)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Merz Investigational Site #0490189
Bad Soden, Germany
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.